Henning Steinhagen, Ph.D., has been named as president, research and development operations at Aptuit. Dr. Steinhagen joined Aptuit in June 2016 from Grünenthal, where he was senior VP and head of global drug discovery. Aptuit provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry.
Matt Marano was appointed senior VP of business development at Rosa & Co. He was senior VP of commercial development at SolveBio. Rosa & Co. partners with pharma and biopharma clients to reduce risk, optimize the efficient use of program resources, and prioritize candidate targets. PhysioPD Research, Rosa’s quantitative systems pharmacology (QSP) approach, translates biology into customized computer models of physiology, disease, and drug effects.
Walter H. Moos, Ph.D., has been appointed CEO of ShangPharma Innovation. Mohamad Moghadam-Tabrizi was made senior VP, business development. Dr. Moos has served in executive roles in pharmaceutical and biotechnology companies and nonprofit research institutes since the 1980s. Tabrizi previously served in senior and executive level positions in corporate business development at Nektar. ShangPharma Innovation is a leading life science partnering organization that provides high-quality and cost-effective drug development and discovery services, technology, and investment for the pharmaceutical and biotechnology industry.
Daniel Schroen was tapped by Nucleus Biologics as VP of sales. Nucleus is a San Diego-based supplier of premium cell culture products for biotech and pharmaceutical companies throughout North America.